Thomas Steyer Farallon Capital Management
Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Aramark
ARMK
|
+$366M |
| 2 |
XLNX
Xilinx Inc
XLNX
|
+$332M |
| 3 |
RTX Corp
RTX
|
+$299M |
| 4 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$289M |
| 5 |
Broadcom
AVGO
|
+$243M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
IMMU
Immunomedics Inc
IMMU
|
+$498M |
| 2 |
INFO
IHS Markit Ltd. Common Shares
INFO
|
+$299M |
| 3 |
AbbVie
ABBV
|
+$298M |
| 4 |
Palo Alto Networks
PANW
|
+$217M |
| 5 |
Bristol-Myers Squibb
BMY
|
+$215M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 38.5% |
| 2 | Technology | 14.31% |
| 3 | Communication Services | 13.23% |
| 4 | Financials | 10.05% |
| 5 | Industrials | 8.49% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Fate Therapeutics
FATE
$279M
| $273M | 1.64% |
3,000,000
-125,000
| -4% | -$7.76M |
|
|
27
Broadcom
AVGO
$1.75T
| $273M | 1.64% |
+6,229,950
| New | +$243M |
|
28
Blackstone
BX
$108B
| $252M | 1.52% |
3,891,886
+62,550
| +2% | +$3.64M |
|
29
Exelixis
EXEL
$13.4B
| $221M | 1.33% |
11,000,000
+250,000
| +2% | +$5.23M |
|
30
New Oriental
EDU
$8.88B
| $214M | 1.29% |
1,154,300
-214,478
| -16% | -$36.1M |
|
|
WORK
31
DELISTED
Slack Technologies, Inc.
WORK
| $207M | 1.25% |
+4,912,300
| New | +$166M |
|
32
Willis Towers Watson
WTW
$31.8B
| $203M | 1.22% |
962,500
+912,500
| +1,825% | +$188M |
|
|
IPHI
33
DELISTED
INPHI CORPORATION
IPHI
| $199M | 1.2% |
+1,239,800
| New | +$174M |
|
34
Alibaba
BABA
$286B
| $199M | 1.19% |
853,300
+240,715
| +39% | +$66.8M |
|
|
MRTX
35
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $192M | 1.16% |
875,000
| – | – |
|
36
Hilton Worldwide
HLT
$73.5B
| $183M | 1.1% |
1,640,437
+94,560
| +6% | +$9.37M |
|
37
Qiagen
QGEN
$9.1B
| $172M | 1.04% |
+3,071,316
| New | +$164M |
|
38
TransUnion
TRU
$16.2B
| $172M | 1.03% |
1,734,082
-80,050
| -4% | -$7.33M |
|
39
Ascendis Pharma A/S
ASND
$16.6B
| $167M | 1% |
1,000,000
-250,000
| -20% | -$41.3M |
|
40
Howmet Aerospace
HWM
$108B
| $140M | 0.84% |
4,891,479
-2,318,909
| -32% | -$51.6M |
|
|
MXIM
41
DELISTED
Maxim Integrated Products
MXIM
| $137M | 0.82% |
1,542,400
+312,400
| +25% | +$24.6M |
|
|
APLS
42
DELISTED
Apellis Pharmaceuticals
APLS
| $130M | 0.78% |
2,275,000
| – | – |
|
|
43
AbbVie
ABBV
$468B
| $123M | 0.74% |
1,150,000
-3,100,000
| -73% | -$298M |
|
|
AMRS
44
DELISTED
Amyris Inc.
AMRS
| $108M | 0.65% |
17,500,000
+3,500,000
| +25% | +$11.2M |
|
45
Sarepta Therapeutics
SRPT
$1.98B
| $102M | 0.62% |
600,000
| – | – |
|
46
PG&E
PCG
$38.8B
| $90.9M | 0.55% |
7,292,042
| – | – |
|
|
SAGE
47
DELISTED
Sage Therapeutics
SAGE
| $90.8M | 0.55% |
1,050,000
| – | – |
|
|
PLYA
48
DELISTED
Playa Hotels & Resorts
PLYA
| $89.2M | 0.54% |
14,994,867
-15,612,063
| -51% | -$72.4M |
|
49
Lufax Holding
LU
$1.2B
| $76.1M | 0.46% |
+1,339,438
| New | +$80.2M |
|
50
Enanta Pharmaceuticals
ENTA
$392M
| $74.7M | 0.45% |
1,775,000
| – | – |
|
Similar funds
Thomas Steyer's Q4 2020 Portfolio in Review
As of Q4 2020, Thomas Steyer held 166 positions worth $16.6B, up 15% from $14.5B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
Thomas Steyer's Q4 2020 filing shows 39 new, 28 increased, 33 reduced and 30 closed positions. Its largest new stake was Aramark: 15,268,169 shares worth $424M. The largest sale was Immunomedics Inc, an estimated $498M.
By sector, the portfolio is most concentrated in Healthcare at 39% of assets, down from 45% a quarter earlier, followed by Technology and Communication Services.
- Thomas Steyer's largest Q4 2020 buy was Aramark: 15,268,169 shares worth $424M.
- Thomas Steyer added most to Willis Towers Watson in Q4 2020, an estimated $188M increase.
- Thomas Steyer's biggest Q4 2020 reduction was AbbVie, cutting an estimated $298M.
- Thomas Steyer fully exited Immunomedics Inc in Q4 2020, selling an estimated $498M.
- Thomas Steyer's ten largest holdings make up 31% of its $16.6B portfolio in Q4 2020.
- Thomas Steyer opened 39 new positions and closed 30 in Q4 2020.
- Thomas Steyer's portfolio value rose 15% quarter-over-quarter to $16.6B.
Based on Farallon Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.